Community Research and Development Information Service - CORDIS

FP6

INDABIP — Result In Brief

Project ID: 37050
Funded under: FP6-LIFESCIHEALTH
Country: Spain

Early detection of Parkinson disease

Understanding susceptibility to a disease is crucial for early diagnosis and design of preventive therapies. Leading European small and medium-sized enterprises (SMEs) joined forces to identify molecules that can be used to detect Parkinson disease (PD) before its onset.
Early detection of Parkinson disease
Many neurodegenerative disorders are preceded by a pre-symptomatic phase, probably lasting years, during which degeneration and death of neurons occurs before any clinical symptoms. One major challenge of clinical research is to identify these early indications and develop preventive treatment strategies, which aim to control the disease at early stages rather than when irreparable neurological damage has been caused.

With this in mind, the EU-funded project ‘Innovative diagnostic approaches for biomarkers in Parkinson disease’ (Indabip) was designed to identify biomarkers for the early diagnosis of PD. More specifically, scientists aimed to assess the potential of proteins, mRNA, and differentially matured RNAs, as diagnostic tests which can be linked to the onset of cellular dysfunction in the brain areas involved in PD. This way one could detect individuals at risk both for disease onset and progression.

Project partners performed gene expression analyses of parts of the brain from patients affected with PD and detected molecules which could potentially be used to modify the course of PD development. Complete characterisation of these putative biomarkers was performed alongside the experimental outcome of their inhibition in pre-clinical models.

The Indabip project findings shed new light into the mechanism underlying the fundamental dysfunctions of dopaminergic neurons and other target neuronal populations that cause PD. It may also be relevant for other related disorders. Overall, the identification of early biomarkers will serve as diagnostic molecular tools for PD and help to identify new pharmacological targets for therapy.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top